Overhead view of a doctor looking at his clipboard

Pipeline

Aldeyra is dedicated to improving the lives of patients suffering from immune-mediated ocular and systemic diseases. We are advancing a broad pipeline of product candidates diversified by chemical composition, mechanism of action, and clinical indication. 

Our clinical pipeline encompasses three distinct biological mechanisms of action: Reactive Aldehyde Species (RASP) inhibition, Dihydrofolate Reductase (DHFR) inhibition, and Chaperome (CHP) inhibition. The immunological activity of our product candidates may potentially lead to diminished levels of pathological inflammation via the down-regulation of immune cell activation or proliferation.

Ocular Diseases

CompoundMechanismPreclinicalPhase 1Phase 2Phase 3RegistrationNext Anticipated Milestone

Ocular Disease

Reproxalap

Disease Area: Dry Eye Disease

Mechanism: RASP

Next Anticipated Milestone: Phase 3 – Part 1 completion Q4 2019

RASP
Preclinical
Phase 1
Phase 2
Phase 3
Registration
Phase 3 – Part 1 completion Q4 2019

Reproxalap

Disease Area: Allergic Conjunctivitis

Mechanism: RASP

RASP
Preclinical
Phase 1
Phase 2
Phase 3
Registration

ADX-2191

Disease Area: Proliferative Vitreoretinopathy

Mechanism: DHFR

Next Anticipated Milestone: Phase 3 – Part 1 initiation Q4 2019

DHFR
Preclinical
Phase 1
Phase 2
Phase 3
Registration
Phase 3 – Part 1 initiation Q4 2019

ADX-103/10X

Disease Area: Retinal Disease

Mechanism: RASP

Next Anticipated Milestone: Phase 1/2 initiation 2020

RASP
Preclinical
Phase 1
Phase 2
Phase 3
Registration
Phase 1/2 initiation 2020

Undisclosed

Disease Area: Ocular Inflammation

Research Collaboration: Undisclosed

Preclinical
Research Collaboration: Undisclosed
Phase 1
Phase 2
Phase 3
Registration

Systemic Diseases

CompoundMechanismPreclinicalPhase 1Phase 2Phase 3RegistrationNext Anticipated Milestone

Systemic Diseases

Reproxalap

Disease Area: Sjögren-Larsson Syndrome

Mechanism: RASP

RASP
Preclinical
Phase 1
Phase 2
Phase 3
Registration

ADX-1612

Disease Area: Post-Transplant Lymphoproliferative Disorder

Mechanism: CHP

Next Anticipated Milestone: Phase 2 initiation H2 2019

CHP
Preclinical
Phase 1
Phase 2
Phase 3
Registration
Phase 2 initiation H2 2019

ADX-1612

Disease Area: Mesothelioma

Mechanism: CHP

Research Collaboration: Investigator-Sponsored Trial

CHP
Preclinical
Research Collaboration: Investigator-Sponsored Trial
Phase 1
Phase 2
Phase 3
Registration

ADX-1612

Disease Area: Ovarian Cancer

Mechanism: CHP

Research Collaboration: Investigator-Sponsored Trial

CHP
Preclinical
Research Collaboration: Investigator-Sponsored Trial
Phase 1
Phase 2
Phase 3
Registration

ADX-629

Disease Area: Autoimmune Disease / Metabolic Disease

Mechanism: RASP

Next Anticipated Milestone: Phase 1 initiation H2 2019

RASP
Preclinical
Phase 1
Phase 2
Phase 3
Registration
Phase 1 initiation H2 2019

ADX-1615

Disease Area: Autoimmune Disease / Cancer

Mechanism: CHP

CHP
Preclinical
Phase 1
Phase 2
Phase 3
Registration

Undisclosed

Disease Area: Systemic Inflammatory Disease

Mechanism: RASP

Research Collaboration: Janssen | Pharmaceutical Companies of Johnson & Johnson

RASP
Preclinical
Research Collaboration: Janssen | Pharmaceutical Companies of Johnson & Johnson
Phase 1
Phase 2
Phase 3
Registration